CN103182023A - Medicine for treating chronic pharyngitis and preparation method thereof - Google Patents
Medicine for treating chronic pharyngitis and preparation method thereof Download PDFInfo
- Publication number
- CN103182023A CN103182023A CN2013100505868A CN201310050586A CN103182023A CN 103182023 A CN103182023 A CN 103182023A CN 2013100505868 A CN2013100505868 A CN 2013100505868A CN 201310050586 A CN201310050586 A CN 201310050586A CN 103182023 A CN103182023 A CN 103182023A
- Authority
- CN
- China
- Prior art keywords
- radix
- medicine
- parts
- effective ingredient
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000007100 Pharyngitis Diseases 0.000 title claims abstract description 48
- 239000003814 drug Substances 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 229940079593 drug Drugs 0.000 title description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 52
- 239000004615 ingredient Substances 0.000 claims abstract description 29
- 239000000284 extract Substances 0.000 claims abstract description 23
- 239000006228 supernatant Substances 0.000 claims abstract description 7
- 239000007788 liquid Substances 0.000 claims abstract description 5
- 238000002156 mixing Methods 0.000 claims abstract description 5
- 239000006187 pill Substances 0.000 claims abstract description 4
- 239000003826 tablet Substances 0.000 claims abstract description 4
- 241000628997 Flos Species 0.000 claims description 25
- 238000000605 extraction Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 6
- 239000002244 precipitate Substances 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 238000002481 ethanol extraction Methods 0.000 claims description 2
- 239000004518 granules dosage form Substances 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 abstract description 22
- 206010011224 Cough Diseases 0.000 abstract description 19
- 239000000203 mixture Substances 0.000 abstract description 11
- 208000003251 Pruritus Diseases 0.000 abstract description 8
- 230000006870 function Effects 0.000 abstract description 8
- 230000007803 itching Effects 0.000 abstract description 6
- 238000001035 drying Methods 0.000 abstract description 3
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract description 3
- 238000001556 precipitation Methods 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 239000008187 granular material Substances 0.000 abstract description 2
- 241000205585 Aquilegia canadensis Species 0.000 abstract 1
- 241000596154 Belamcanda Species 0.000 abstract 1
- 235000007516 Chrysanthemum Nutrition 0.000 abstract 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 240000002948 Ophiopogon intermedius Species 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000011812 mixed powder Substances 0.000 abstract 1
- 238000004064 recycling Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 22
- 210000003800 pharynx Anatomy 0.000 description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 210000003734 kidney Anatomy 0.000 description 11
- 206010062717 Increased upper airway secretion Diseases 0.000 description 10
- 208000002193 Pain Diseases 0.000 description 10
- 230000036407 pain Effects 0.000 description 10
- 208000026435 phlegm Diseases 0.000 description 10
- 206010068319 Oropharyngeal pain Diseases 0.000 description 8
- 230000003110 anti-inflammatory effect Effects 0.000 description 8
- 230000007812 deficiency Effects 0.000 description 7
- 231100000614 poison Toxicity 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 239000003440 toxic substance Substances 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 239000003172 expectorant agent Substances 0.000 description 6
- 230000003419 expectorant effect Effects 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- -1 flavone compound Chemical class 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 239000000341 volatile oil Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 208000031971 Yin Deficiency Diseases 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000035807 sensation Effects 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 3
- 208000019505 Deglutition disease Diseases 0.000 description 3
- 206010020565 Hyperaemia Diseases 0.000 description 3
- 206010020880 Hypertrophy Diseases 0.000 description 3
- 241000208125 Nicotiana Species 0.000 description 3
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- 208000033809 Suppuration Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 208000016150 acute pharyngitis Diseases 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 208000017574 dry cough Diseases 0.000 description 3
- 206010013781 dry mouth Diseases 0.000 description 3
- 239000000428 dust Substances 0.000 description 3
- 210000003026 hypopharynx Anatomy 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000002751 lymph Anatomy 0.000 description 3
- 238000005057 refrigeration Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 238000002137 ultrasound extraction Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 206010013952 Dysphonia Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 208000015220 Febrile disease Diseases 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000004378 Glycyrrhizin Substances 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000010473 Hoarseness Diseases 0.000 description 2
- RISXUTCDCPHJFQ-UHFFFAOYSA-N Irisflorentin Chemical compound COC1=C(OC)C(OC)=CC(C=2C(C3=C(OC)C=4OCOC=4C=C3OC=2)=O)=C1 RISXUTCDCPHJFQ-UHFFFAOYSA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 206010043458 Thirst Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 208000005946 Xerostomia Diseases 0.000 description 2
- 230000000954 anitussive effect Effects 0.000 description 2
- 229940124584 antitussives Drugs 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000013116 chronic cough Diseases 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
- 238000007596 consolidation process Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000000916 dilatatory effect Effects 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- OBBCRPUNCUPUOS-UHFFFAOYSA-N tectorigenin Chemical compound O=C1C2=C(O)C(OC)=C(O)C=C2OC=C1C1=CC=C(O)C=C1 OBBCRPUNCUPUOS-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- IECBDTGWSQNQID-JGVFFNPUSA-N (1r,5s)-4,6,6-trimethylbicyclo[3.1.1]hept-3-en-7-one Chemical compound CC1=CC[C@@H]2C(C)(C)[C@H]1C2=O IECBDTGWSQNQID-JGVFFNPUSA-N 0.000 description 1
- CWVRJTMFETXNAD-BMNNCGMMSA-N (1s,3r,4s,5r)-3-[(e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-1,4,5-trihydroxycyclohexane-1-carboxylic acid Chemical compound O[C@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-BMNNCGMMSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- SRWKSFRBHIWJSD-UHFFFAOYSA-N 6-cyclohexylhexan-1-ol Chemical compound OCCCCCCC1CCCCC1 SRWKSFRBHIWJSD-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- QIIDATRCGITYRZ-UHFFFAOYSA-N Catalpol Natural products OCC1OC(OC2OC=CC3C(O)C(=C(CO)C23)O)C(O)C(O)C1O QIIDATRCGITYRZ-UHFFFAOYSA-N 0.000 description 1
- IECBDTGWSQNQID-UHFFFAOYSA-N Chrysanthenon Natural products CC1=CCC2C(C)(C)C1C2=O IECBDTGWSQNQID-UHFFFAOYSA-N 0.000 description 1
- IECBDTGWSQNQID-SFYZADRCSA-N Chrysanthenone Natural products CC1=CC[C@H]2C(C)(C)[C@@H]1C2=O IECBDTGWSQNQID-SFYZADRCSA-N 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 241000201295 Euphrasia Species 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- LNQCUTNLHUQZLR-VNPYQEQNSA-N Iridin Natural products O(C)c1c(O)c2C(=O)C(c3cc(OC)c(OC)c(O)c3)=COc2cc1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 LNQCUTNLHUQZLR-VNPYQEQNSA-N 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- DEMKZLAVQYISIA-UHFFFAOYSA-N Liquirtin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-UHFFFAOYSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010067994 Mucosal atrophy Diseases 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- CXFDIAPJVDDVDX-UHFFFAOYSA-N Sheganone Natural products COc1cc(CC(=O)c2c(O)cc3OCOc3c2OC)cc(OC)c1OC CXFDIAPJVDDVDX-UHFFFAOYSA-N 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 206010065954 Stubbornness Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 108010074506 Transfer Factor Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229940025250 camphora Drugs 0.000 description 1
- 239000010238 camphora Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- LHDWRKICQLTVDL-PZYDOOQISA-N catalpol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2[C@@]3(CO)O[C@H]3[C@@H](O)[C@@H]2C=CO1 LHDWRKICQLTVDL-PZYDOOQISA-N 0.000 description 1
- UXSACQOOWZMGSE-UHFFFAOYSA-N catalposide Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(OC(=O)C=3C=CC(O)=CC=3)C2C=CO1 UXSACQOOWZMGSE-UHFFFAOYSA-N 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- FSBUXLDOLNLABB-ISAKITKMSA-N echinacoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O[C@@H](OCCC=2C=C(O)C(O)=CC=2)[C@@H]1O FSBUXLDOLNLABB-ISAKITKMSA-N 0.000 description 1
- NJYVDFDTLLZVMG-UHFFFAOYSA-N echinacoside Natural products CC1OC(OC2C(O)C(OCCc3ccc(O)c(O)c3)OC(COC4OC(CO)C(O)C(O)C4O)C2OC(=O)C=Cc5cc(O)cc(O)c5)C(O)C(O)C1O NJYVDFDTLLZVMG-UHFFFAOYSA-N 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000001408 fungistatic effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- LNQCUTNLHUQZLR-OZJWLQQPSA-N iridin Chemical compound OC1=C(OC)C(OC)=CC(C=2C(C3=C(O)C(OC)=C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C=C3OC=2)=O)=C1 LNQCUTNLHUQZLR-OZJWLQQPSA-N 0.000 description 1
- 229930182489 iridoid glycoside Natural products 0.000 description 1
- 150000008145 iridoid glycosides Chemical class 0.000 description 1
- KRZBCHWVBQOTNZ-DLDRDHNVSA-N isochlorogenic acid Natural products O[C@@H]1[C@H](C[C@@](O)(C[C@H]1OC(=O)C=Cc2ccc(O)c(O)c2)C(=O)O)OC(=O)C=Cc3ccc(O)c(O)c3 KRZBCHWVBQOTNZ-DLDRDHNVSA-N 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- LHDWRKICQLTVDL-UHFFFAOYSA-N methyl iridoid glycoside Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(O)C2C=CO1 LHDWRKICQLTVDL-UHFFFAOYSA-N 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 229930189407 platycodin Natural products 0.000 description 1
- 229930185936 platycogenic acid Natural products 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- UYLQOGTYNFVQQX-UHFFFAOYSA-N psi-tectorigenin Natural products COC1=C(O)C=C(O)C(C2=O)=C1OC=C2C1=CC=C(O)C=C1 UYLQOGTYNFVQQX-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 150000005856 steroid saponins Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- OYUJPVCKGSEYDD-UHFFFAOYSA-N tectorigenin Natural products COc1c(O)cc2OCC(C(=O)c2c1O)c1ccc(O)cc1 OYUJPVCKGSEYDD-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 208000026844 throat symptom Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a medicine for treating chronic pharyngitis. The medicine is prepared from the following ingredients by weight: 15.0-20.7 parts of honeysuckle, 13.8-22.5 parts of chrysanthemum, 9.4-13.2 parts of blackberry lily, 8.6-14.4 parts of radix platycodi, 9.4-13.2 parts of radix rehmanniae, 8.6-14.4 parts of radix scrophulariae, 9.4-13.2 parts of dwarf lilyturf tuber, and 5.6-8.6 parts of liquorice. The medicine is simple and reasonable in composition, and has the functions of nourishing yin and moistening lung, clearing away heat and toxic materials, clearing heat from throat, and relieving cough and itching. The invention further discloses a preparation method of the medicine, which comprises the following steps: drying, crushing and mixing each ingredient based on the weight part, placing the mixed powder into a supersonic extractor, adding 70% ethanol to extract effective components so as to obtain the alcohol extract of the effective components, placing the extract still for 48-72h, taking and filtering alcohol precipitation supernatant, recycling ethanol to obtain the concentrated extract of the effective components, and preparing oral liquid, pills, tablets or granules according to requirements.
Description
Technical field
The invention belongs to the Chinese medicine preparation technical field, relate generally to a kind of medicine for the treatment of chronic pharyngitis and preparation method thereof.
Background technology
Pharyngitis is the hals,Nasen und Ohrenheilkunde commonly encountered diseases, is pharyngeal mucosa, the inflammation of submucous tissue; Can be local inflammation, also can be the part of upper respiratory tract chronic inflammatory disease.Different according to the length of the course of disease and pathological change character are divided into acute pharyngitis, chronic pharyngitis two big classes.Chronic pharyngitis patient mainly shows as pharyngeal cavity drying, foreign body sensation, itch sense, irritable cough etc.The course of disease is long, and the symptom stubbornness be difficult for to be cured, and multiplely is born in the adult, and city sickness rate height is especially multiple in the majority with occupations such as teacher, singers.Because it shows effect repeatedly, brings many discomforts to the patient.
Generally chronic pharyngitis is divided into chronic simple pharyngitis, chronic hypertrophic pharyngitis, chronic atrophic pharyngitis clinically.
Doctor trained in Western medicine thinks that the chronic pharyngitis pathogenesis is: 1. acute pharyngitis shows effect repeatedly; 2. the upper respiratory tract chronic inflammatory disease stimulates; 3. tobacco and wine are excessive, and dust, harmful gas etc. stimulate and happiness food irritable food; 4. occupational factor (teacher and chanteur) and physical factors; 5. systemic factor: anemia, dyspepsia, heart disease, chronic bronchitis, endocrine regulation etc.
Latest modern technological studies show that: viral infection plays an important role in the morbidity of infective pharyngitis, is mainly Epstein-Barr virus and adenovirus; Bacterial infection still is one of important paathogenic factor of pharyngitis, and pathogenic bacterium are mainly Hemolytic streptococcus, secondly bites blood bacillus, mycoplasma pneumoniae etc. for staphylococcus aureus, influenza.In addition, the symptom of allergic inflammation such as the pharyngeal gargalesthesia paroxysmal of chronic pharyngitis patient tool dry cough shows that the allergy factor also has important function in the chronic pharyngitis morbidity.
The traditional Chinese medical science thinks that chronic pharyngitis is in the majority with " hypopyretic laryngalgia ".Its etiology and pathogenesis is YIN-deficiency of the lung and kidney often, and internal organs are deficient, consumption impairment of YIN branch, and hyperactivity of deficient fire causes in throat; Or because acute pharyngitis due to wind-heat shows effect repeatedly, surplus evil the delay; Or dust, foul smell stimulate, and the hobby tobacco and wine are pungent, and impairment caused by overstrain excessively waits and causes.The deficiency of YIN is deficiency of body fluid then, and throat loses in moistening foster, and furthermore asthenic fire is followed through last inflammation; Deficiency of the kidney yin, network is in lung on the passages through which vital energy circulates of kidney, and deficiency of the kidney yin whenever causes the also deficiency of YIN of lung, and hyperactivity of deficient fire is satisfied to sore throat.In addition, steam on the asthenic fire, bright Tianjin becomes expectorant, venation numbness resistance in addition, and disorder of QI movement causes stagnation of QI expectorant and coagulates phlegm-fire pent-up.
Western medicine is dispeled the cause of disease to adopt of the treatment of chronic pharyngitis more, gives up tobacco and wine, avoids methods such as dust and harmful gas.The main iodine preparation of using for oral administration is used external treatmenies such as laser, radio frequency in case of necessity, or local branch injection transfer factor etc.
The traditional Chinese medical science adopts Drug therapy to the treatment of chronic pharyngitis more, with YIN supplementing and fluids increasing, and nourishing the lung and kidney, the sore-throat relieving that wets one's whistle is main, is aided with heat-clearing and toxic substances removing, dissipating phlegm and resolving masses is principle for the treatment of.Can avoid the chronic pharyngitis patient at each antibiotics of the medium-term and long-term abuse of western medicine process, cause the damage of internal organs such as patient's taste Liver and kidney.
Summary of the invention
One of purpose of the present invention is to provide a kind of Chinese patent medicine for the treatment of chronic pharyngitis, and this medicine prescription is concisely reasonable, has nourishing YIN and moistening the lung, heat-clearing and toxic substances removing, clearing throat, the effect that antitussive is antipruritic.
Another object of the present invention provides the preparation method for the treatment of chronic pharyngitis medicine.
The invention is for realizing one of goal of the invention, by the following technical solutions:
The medicine of the treatment chronic pharyngitis of the invention, made by following components by part by weight:
Flos Lonicerae 15.0-20.7, Flos Chrysanthemi 13.8-22.5, Rhizoma Belamcandae 9.4-13.2, Radix Platycodonis 8.6-14.4, Radix Rehmanniae 9.4-13.2, Radix Scrophulariae 8.6-14.4, Radix Ophiopogonis 9.4-13.2, Radix Glycyrrhizae 5.6-8.6.
Further, each component is preferably:
Flos Lonicerae 16.0-19.8, Flos Chrysanthemi 15.1-21.0, Rhizoma Belamcandae 9.9-12.8, Radix Platycodonis 9.3-13.6, Radix Rehmanniae 9.9-12.8, Radix Scrophulariae 9.3-13.6, Radix Ophiopogonis 9.9-12.8, Radix Glycyrrhizae 6.2-8.1.
Further, each component is more preferably:
Flos Lonicerae 17.3-19.2, Flos Chrysanthemi 16.8-19.8, Rhizoma Belamcandae 10.5-12, Radix Platycodonis 10.2-12.3, Radix Rehmanniae 10.5-12.0, Radix Scrophulariae 10.2-12.3, Radix Ophiopogonis 10.5-12.0, Radix Glycyrrhizae 6.8-7.8.
The preparation method of the medicine of the treatment chronic pharyngitis of the invention:
Comprise will be by weight each component oven dry, make the step of coarse powder 250-850um or 24 orders-65 order, mixing; Powder is inserted in the supersound extraction device, add 70% ethanol extraction effective ingredient, make the step of effective ingredient alcohol extract; Left standstill 48-72 hour, and made the precipitate with ethanol supernatant; Filter, reclaim ethanol, make the step of effective ingredient concentrated extract.
Further, when making the effective ingredient alcohol extract, comprise that adding 5-7 doubly measures 70% soak with ethanol 0.5-1.0 hour of ingredients weight parts, continue to add 70% ethanol and doubly measure to 8-10, extracted 1.0-1.5 hour down at 45-55 ℃, collect the step of effective ingredient alcohol extract one.
Further, when making the effective ingredient alcohol extract, also comprise adding 70% ethanol that 5-7 doubly measures ingredients weight parts again, extracted 0.5-1.0 hour down at 45-55 ℃, collect the step of effective ingredient alcohol extract two.
Further, also comprise the step of the effective ingredient concentrated extract being made oral liquid, pill, tablet, granule dosage form.
In the composition of preparation medicine of the present invention, the characteristic of each component is as follows:
Flos Lonicerae: sweet, cold, Xin Xiang; Heat-clearing and toxic substances removing, wind-heat dissipating.Contain compositions such as cyclohexanhexanol, flavonoid, inositol, Saponin and tannin, comprise chlorogenic acid, isochlorogenic acid, luteolin etc. and based on the volatile oil of the pure and mild linalool of Flos Lonicerae.Flos Lonicerae all has stronger inhibitory action to various pathogens such as staphylococcus aureus, dysentery bacteriums, multiple pathogenic microorganisms such as leptospira, influenza virus and pathogenic moulds also there is inhibitory action, also has effects such as tangible antiinflammatory and refrigeration function and excited maincenter, enhancing immune function.Be usually used in the carbuncle furuncle, sore throat, erysipelas, toxic-heat and blood stasis, anemopyretic cold, epidemic febrile disease heating.
Flos Chrysanthemi: sweet, bitter, be slightly cold; Return lung, Liver Channel.Contain that to mainly contain Borneolum Syntheticum, Camphora, chrysanthenone be compositions such as main volatile oil, adenine, choline, echinacoside, aminoacid, vitamin.The effect of have dispelling wind, heat clearing away, make eye bright, detoxifying.Diseases such as main treatment headache, dizzy, conjunctival congestion, irritable feverish sensation of chest and heart, furuncle, toxic swelling.Modern pharmacological research shows, Flos Chrysanthemi has treatment coronary heart disease, brings high blood pressure down, prevents hyperlipidemia, antibiotic, antiviral, antiinflammatory, the anti-ageing multiple pharmacologically active of waiting for a long time.Wherein flavone compound, triterpenoid compound and volatile oil are its main effective ingredient.
Rhizoma Belamcandae: bitter, cold; Go into lung, Liver Channel.The function heat-clearing and toxic substances removing, throat, expectorant saliva.Main iridin, irisflorentin, sheganone, peaceful, the tectorigenin of floral leaf of containing; Have resisting pathogenic microbes effect, antiinflammatory action, refrigeration function.Laryngopharynx swelling and pain and the accumulation and obstruction of sputum that are used for due to wind heat, the expectorant heat more, diseases such as cough and asthma.
Radix Scrophulariae: sweet in the mouth, hardship, salty; Return lung, stomach, kidney channel.The function clearing away heat and cooling blood, detoxifcation YIN nourishing, eliminating stagnation sore-throat relieving.The main compositions such as alkaloid, saccharide, sterol, aminoacid, fatty acid, volatile oil, carotene and retinoid that contain.Have antibiotic, blood sugar lowering, calmness, blood pressure lowering, heart tonifying, blood vessel dilating effect.The maculae caused by violent heat pathogen that are used for, constipation, hectic fever due to YIN-deficiency chronic cough, conjunctival congestion scrofula, carbuncle sore tumefacting virus are hindered in consumption of YIN caused by febrile disease, pharyngalgia excessive thirst, Tianjin more.
Radix Rehmanniae: sweet, cold; GUIXIN, liver, kidney channel.Clearing away heat and cooling blood, yin nourishing is promoted the production of body fluid.Chemical constituent wherein again based on iridoid glycosides (content of catalpol is the highest), also contains saccharide, several amino acids, inorganic elements and other organic principles etc. based on glycoside.Have effects such as blood sugar lowering, hemostasis, anticoagulation, anti inflammatory immunity, anti-hepatic injury, be used for calentura crimson tongue excessive thirst more, yin asthenia generating intrinsic heat, the hectic fever due to YIN-deficiency consumptive fever, is quenched one's thirst at interior-heat, spits blood, and epistaxis is sent out the speckle dermexanthesis.
Radix Platycodonis: bitter in the mouth, suffering, flat; Return lung.Lung qi dispersing, sore-throat relieving eliminates the phlegm, evacuation of pus.Contain kikyosaponin (Platycodin), platycogenic acid, inulin, compositions such as platycodonin have and eliminate the phlegm and effects such as antitussive, antiinflammatory, calmness, analgesia and refrigeration function and blood sugar lowering, antiulcer, blood vessel dilating.Be mainly used in cough with copious phlegm, fullness in the chest and hypochondriac pain, pharyngalgia hoarseness, lung abscess vomiting pus, diseases such as skin infection difficulty in discharging of pus.
Radix Ophiopogonis: sweet, cold, clear and rich; GUIXIN, lung, stomach warp.The heat of the kind lung that clears away heart-fire and yin nourishing relieving restlessness, holding concurrently can clear and rich gastrointestinal and quench the thirst and moisturize.Main multiple steroid saponin, dihydro homoisoflavone, volatile oil, Sitosterolum, the aminoacid etc. of containing.Have calmness, arrhythmia, increase coronary flow, improve cellular immunization, antifatigue effect.The dryness of the lung dry cough that are used for more, deficiency of YIN consumptive disease is coughed, the sore throat pharyngalgia, Tianjin wound is thirsty, and interior-heat is quenched one's thirst, vexed insomnia, diseases such as dryness of the intestine constipation.
Radix Glycyrrhizae: property is flat, sweet in the mouth; Return 12 warps.Detoxifcation arranged, eliminate the phlegm, pain relieving, spasmolytic be so that pharmacological action such as anticancer.Give birth to and relieve inflammation or internal heat with being longer than, with heat-clearing and toxic substances removing, nourishing the lung to arrest cough power wins.Be used for phlegm-heat cough, laryngopharynx swelling and pain etc.The ripe usefulness exterior cold of loosing is gone pharyngalgia, except pathogenic heat, and slow healthy energy, yin nourishing blood, tonifying the spleen and stomach, lung moistening.Radix Glycyrrhizae main component triterpenoid compound (glycyrrhizin etc.), flavone compound (liquirtin etc.), aminoacid etc.Glycyrrhizin and Flavonoid substances are most important biological active substanceies in the Radix Glycyrrhizae.Radix Glycyrrhizae has the function of antiinflammatory and resistance attitude reflection, can protect the digestive system effect, have concurrently have the central relieving cough and asthma, regulate body's immunity and detoxifcation, the effect of adrenocortical hormone sample.
This side forms, and is scientific and reasonable.Flos Lonicerae, Flos Chrysanthemi heat-clearing and toxic substances removing, wind-heat dissipating are monarch in the side; Radix Platycodonis, Rhizoma Belamcandae lung qi dispersing eliminate the phlegm, relieving sore throat and pain is minister; Radix Scrophulariae, Radix Rehmanniae detoxifcation removing heat from blood, Yin-nourishing and body fluid promoting, Radix Ophiopogonis nourishing YIN and moistening the lung, Radix Glycyrrhizae clear away heart-fire lung, yin nourishing, coordinating the actions of various ingredients in a prescription makes for assistant altogether.All medicines share, and play the yin nourishing sore-throat relieving altogether, heat-clearing and toxic substances removing, YIN nourishing removing heat from blood, the merit of reducing swelling and alleviating pain.
Pharmacological research:
Pharmacological research has confirmed that medicine of the present invention has following pharmacological action at present:
1, bacteriostasis: (plate punch method extracorporeal bacteria inhibitor test sees Table 1)
The external fungistatic effect laboratory test results of table 1 the present invention: (pharmacological evaluation)
The result shows: medicine of the present invention has inhibitory action to 4 kinds of common pathogenic bacterium.
2, antiinflammatory action: cause mice ear with Oleum Tiglii, with medicine 5.0ml/kg of the present invention, 10.0ml/kg, 15.0ml/kg gastric infusion, observe the mice ear situation.
The result shows: medicine of the present invention can obviously suppress the mice ear degree, demonstrates antiinflammatory action.
3, acute toxicity test: adopt medicine condensed water decoct of the present invention (1:4) to gavage mice, by every day 2 times, each 30ml/kg.The mice activity has decline slightly after the administration.4hr after the drug withdrawal, transference cure.The back is observed after gavaging 7 continuously.
The result shows: experiment mice is strong depositing all, and untoward reaction is not seen in the no abnormal variation of conscience spleen lung kidney.
Clinical observation
Drug therapy chronic pharyngitis 200 examples of the present invention and contrast treatment 150 examples.
Data, method and conclusion
1, physical data
1.1 case source: 200 examples, male's 120 examples wherein, women's 80 examples, the age is 16 examples below 10 years old, 10 years old～20 years old 26 examples, 258 examples more than 20 years old.
1.2 case is selected
1.2.1 diagnostic criteria: formulate with reference to " Chinese traditional medical diagnose routine " (1998).
Diagnosis basis
1.2.1.1 pharyngeal scorching hot, redness, dysphagia, pain, dried itching.
1.2.1.2 pharyngeal mucous membrane hyperemia, pharynx rear wall, lymph foilicie hyperplasia and funiculus lateralis have redness.
1.2.1.3 aversion to cold can be arranged, heating, headache or xerostomia and the pain etc.
Dialectical foundation:
Painful or the itching throat of pharynx has foreign body sensation, and the irritative cough is arranged, and is vexed uncomfortable in chest, xerostomia and glue, and pharyngeal chronic congestion, it is agglomerating that the pharynx rear wall has a plurality of folliculus to assemble, and tonsil is big or little, red tongue or light red, tongue is thick greasy slightly in vain, and soft pulse is soft and count.
1.2.2 include the case standard in: meet the diagnostic criteria of chronic pharyngitis, dialectical standard.
1.2.3 get rid of case standard (comprising the rejecting standard).
1.2.3.1 be associated with severe cardiac, lung, kidney, liver primary disease person, the psychotic.
1.2.3.2 all not medications in accordance with regulations can't be judged curative effect etc.
2, Therapeutic Method: consumption: each 30ml, every day 3 times.
Usage: oral.
The course for the treatment of: 10 days is a course for the treatment of, is divided into three courses for the treatment of.
3, observation index:
3.1 curative effect determinate standard
3.1.1 recovery from illness: local red and swollen, scorching hot, the dysphagia of throat, pain, the dried disappearance of itching, the hypertrophy lymphocyte disappears substantially.
3.1.2 take a turn for the better: local swollen painful disappearance of throat, but still have hyperemia, dysphagia scorching hotly obviously alleviates.
3.1.3 do not heal: the throat symptom is not seen improvement.
4.1 clinical treatment curative effect: see Table 2.
Table 2 clinical treatment curative effect (%)
From clinical control therapeutic outcome (table 2) as can be seen, medicine of the present invention is 93.0% for the treatment total effective rate of chronic pharyngitis.Wherein, cure rate 75.0%, improvement rate 18.0%, inefficiency 7.0%, general curative effect is remarkable.
4.2 clinical control treatment curative effect: see Table 3.
Table 3 clinical control treatment (%)
From clinical control therapeutic outcome (table 3) as can be seen, contrast other treatment chronic pelvic inflammatory disease medicine, curative effect of medication of the present invention is more remarkable.Wherein, the treatment group is taken medicine of the present invention, and matched group 1 is taken Yanyan slice, and matched group 2 is taken the Jinsangliyan capsule.
4.3 untoward reaction: do not see obvious side reaction in the therapeutic process.
4.4 conclusion:
The practice for the treatment of for many years shows, medicine of the present invention is applicable to because of YIN-deficiency of the lung and kidney, consumption impairment of YIN branch, pharyngeal mistake is supported, or the evil diseases such as the laryngopharynx swelling and pain that causes in pharynx, the hoarseness of crying out, thirsty expectorant Huang that stagnate, especially chronic pharyngitis, tonsillitis due to lung-dryness syndrome due to deficiency of YIN or the stagnation of phlegm-heat are seen that above-mentioned disease person's curative effect is particularly remarkable, toxic and side effects is little, and seldom recurrence more.By clinical observation, follow up a case by regular visits to feedback, add up to efficient and reach more than 92%.The present invention is through scientific research and in conjunction with modern ultrasonic extraction process technology, and demonstration is final determines through studying repeatedly for many years, putting into practice.The present invention treats all kinds chronic pharyngitis and other dermatosis is evident in efficacy, and more the difficult recurrence in back and cost are lower.
The case case
The week certain, man, 20 years old.Go to a doctor in April, 2011, suffers from chronic pharyngitis, and cough is serious, and body constitution is poor, easy catching a cold.Played the cough of easy repeated cold in 3 years old, often beat garter, take antibiotic, went to a hospital to see a doctor in 7 years old, pharynx back ancient piece of jade, round, flat and with a hole in its centre lymph foilicie hyperplasia, cough throughout the year, dry pharynx, retch, itching throat, eyes itch, oral ulcer repeatedly.From frequent cough in 2004, the few expectorant of dry cough did not almost stop, and throat is dried coughs up sound constantly, and resistance is also poor now, easy catching a cold, lassitude, and appetite is normal, and insomnia is arranged, and defecation is normal.Repeatedly fail to respond to any medical treatment.Take drug mixture of the present invention, symptom obviously alleviates after 1 week, and the complete obiteration of first quarter moon symptom is advised and continued to strengthen 1 week of taking medicine, and does not see recurrence so far.
Zhao, man 35 years old, teacher.Dry pharynx is scratchy, foreign body sensation, 1 year surplus, fatiguability on ordinary days, dreaminess, constipation, in time, cough up phlegm, amount is less and yellow.Check: pharynx rear wall drying, follicle hypertrophy, color is light red.Body of the tongue is light red fat slightly, and tongue is few, thready and rapid pulse without strength.Oral drug mixture of the present invention is after 1 week, and cough, expectoration symptom are obviously improved, and pharyngalgia obviously alleviates after 10 days, advises and continues to take medicine 10 days as a means of consolidation.
Lee, woman, 40 years old.Pharyngopathy 3-4, dry mouth and throat and like drink, itching of the throat is then coughed, and pharyngalgia radiation sometimes and breast can cause cardiopalmus; Sometimes pharyngeal have burn feeling, then a thick Huang of abundant expectoration.Inspection sees that pharynx rear wall lymph follicle is dispersed in hypertrophy, the part mucosal atrophy, and lateral pharyngeal band enlargement and red is diffusivity hyperemia.Thin and greasy fur, the root Huang is thick, stringy and tense pulse, obstinate.Take drug mixture of the present invention, symptom is obviously improved after 1 week, and symptom disappears substantially behind the first quarter moon, advises 1 week of continuing to take medicine as a means of consolidation, so far recurrence.
Description of drawings
Fig. 1 is the invention pharmaceutical preparation schematic flow sheet;
The specific embodiment
Embodiment one
The medicine of the treatment chronic pharyngitis of present embodiment, made by following each component by weight:
Flos Lonicerae 15.0, Flos Chrysanthemi 22.5, Rhizoma Belamcandae 9.4, Radix Platycodonis 14.4, Radix Rehmanniae 9.4, Radix Scrophulariae 14.4, Radix Ophiopogonis 9.4, Radix Glycyrrhizae 5.6.
Embodiment two
The medicine of the treatment chronic pharyngitis of present embodiment, made by following each component by weight:
Flos Lonicerae 18.5, Flos Chrysanthemi 18.5, Rhizoma Belamcandae 11.1, Radix Platycodonis 11.1, Radix Rehmanniae 11.1, Radix Scrophulariae 11.1, Radix Ophiopogonis 11.1, Radix Glycyrrhizae 7.4.
Embodiment three
The medicine of the treatment chronic pharyngitis of present embodiment, made by following each component by weight:
Flos Lonicerae 20.7, Flos Chrysanthemi 13.8, Rhizoma Belamcandae 13.2, Radix Platycodonis 8.6, Radix Rehmanniae 13.2, Radix Scrophulariae 8.6, Radix Ophiopogonis 13.2, Radix Glycyrrhizae 8.6.
The medicine of above-described embodiment 1-3, in conjunction with Fig. 1, the preparation method of making mixture is:
At first the component of each weight portion is dried, is made coarse powder 250-850um or 24 orders-65 order, mixing; Powder is put into the supersound extraction device, and adding 5-7 doubly measures 70% soak with ethanol 30-60 minute of each component total weight parts, continues to add 70% ethanol and doubly measures to 8-10, and extraction is 1.0-1.5 hour under 45-55 ℃, collection effective ingredient alcohol extract one; Add 5-7 again and doubly measure 70% ethanol, extracted 0.5-1.0 hour down at 45-55 ℃, collect effective ingredient alcohol extract two; Merge extracted twice liquid, low temperature 2-8 ℃ storage was left standstill 48-72 hour, made the precipitate with ethanol supernatant; Incline and get supernatant, filter, reclaim ethanol, make the effective ingredient concentrated extract.The purified water that adds 3-4 times of effective ingredient concentrated extract weight portion, mixing left standstill 24-36 hour, made the water precipitating supernatant; Incline and get supernatant, filter, add purified water to nearly full dose, regulate pH value to 4.0-6.0, standardize solution, fill namely gets the mixture finished product.
Medicine of the present invention needs at concrete treatment, can be made into dosage forms such as oral liquid, pill, tablet, granule, so that take and carry.
Pharmaceutical preparation of the present invention as extracting solvent, adopts ultrasonic extraction (being also referred to as extraction) Chinese crude drug effective ingredient with 70% ethanol.With 70% ethanol as extracting solvent, wide adaptability, impurity is few, the finished product mouthfeel is limpid, color and luster is shinny.Ultrasonic extraction has extracts the unique advantage that temperature is low, extraction ratio is high, extraction time is short, is applicable to the extraction of Chinese crude drug and various animal and plant effective contents.With technology such as traditional water extract-alcohol precipitation relatively; extraction ratio improves 50%-100%; extraction time (minute) shorten more than 1/2; extract temperature and be reduced to 40-60 ℃; being more conducive to the protection of active ingredient, is to substitute traditional aqueous extraction-alcohol precipitation technology method to realize modern high technology means efficient, that the energy-saving and environmental protection formula is extracted.
Claims (7)
1. medicine for the treatment of chronic pharyngitis is characterized in that: made by following components by part by weight:
Flos Lonicerae 15.0-20.7, Flos Chrysanthemi 13.8-22.5, Rhizoma Belamcandae 9.4-13.2, Radix Platycodonis 8.6-14.4, Radix Rehmanniae 9.4-13.2, Radix Scrophulariae 8.6-14.4, Radix Ophiopogonis 9.4-13.2, Radix Glycyrrhizae 5.6-8.6.
2. the medicine for the treatment of chronic pharyngitis according to claim 1, it is characterized in that: each component is preferably:
Flos Lonicerae 16.0-19.8, Flos Chrysanthemi 15.1-21.0, Rhizoma Belamcandae 9.9-12.8, Radix Platycodonis 9.3-13.6, Radix Rehmanniae 9.9-12.8, Radix Scrophulariae 9.3-13.6, Radix Ophiopogonis 9.9-12.8, Radix Glycyrrhizae 6.2-8.1.
3. the medicine for the treatment of chronic pharyngitis according to claim 1 is characterized in that: each component more preferably:
Flos Lonicerae 17.3-19.2, Flos Chrysanthemi 16.8-19.8, Rhizoma Belamcandae 10.5-12, Radix Platycodonis 10.2-12.3, Radix Rehmanniae 10.5-12.0, Radix Scrophulariae 10.2-12.3, Radix Ophiopogonis 10.5-12.0, Radix Glycyrrhizae 6.8-7.8.
4. preparation method for preparing the medicine of the described treatment chronic pharyngitis of claim 1-3 is characterized in that:
Comprise each component oven dry, powder process that will be by weight, the step of mixing; Powder is inserted in the supersound extraction device, add 70% ethanol extraction effective ingredient, make the step of effective ingredient alcohol extract; Left standstill 48-72 hour, and made the precipitate with ethanol supernatant; Filter, reclaim ethanol, make the step of effective ingredient concentrated extract.
5. preparation method according to claim 4, it is characterized in that: when making the effective ingredient alcohol extract, comprise that adding 5-7 doubly measures 70% soak with ethanol 0.5-1.0 hour of ingredients weight parts, continue adding 70% ethanol doubly measures to 8-10, extracted 1.0-1.5 hour down at 45-55 ℃, collect the step of effective ingredient alcohol extract one.
6. preparation method according to claim 4 is characterized in that: when making the effective ingredient alcohol extract, also comprise adding 70% ethanol that 5-7 doubly measures ingredients weight parts again, extracted 0.5-1.0 hour down at 45-55 ℃, collect the step of effective ingredient alcohol extract two.
7. preparation method according to claim 4 is characterized in that: also comprise the step of the effective ingredient concentrated extract being made oral liquid, pill, tablet, granule dosage form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013100505868A CN103182023A (en) | 2013-02-07 | 2013-02-07 | Medicine for treating chronic pharyngitis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013100505868A CN103182023A (en) | 2013-02-07 | 2013-02-07 | Medicine for treating chronic pharyngitis and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103182023A true CN103182023A (en) | 2013-07-03 |
Family
ID=48673638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013100505868A Pending CN103182023A (en) | 2013-02-07 | 2013-02-07 | Medicine for treating chronic pharyngitis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103182023A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103933326A (en) * | 2013-09-22 | 2014-07-23 | 李修奇 | Traditional Chinese medicine formula tea drink for treating chronic pharyngolaryngitis |
| CN104645010A (en) * | 2013-11-22 | 2015-05-27 | 李士干 | Acute and chronic pharyngitis tea and preparation process thereof |
| CN105106646A (en) * | 2015-09-12 | 2015-12-02 | 淄博齐鼎立专利信息咨询有限公司 | Medicinal preparation for treating chronic pharyngitis |
| CN105343503A (en) * | 2015-11-30 | 2016-02-24 | 中国人民解放军第二军医大学 | Medicine composition for treating sphagitis and application thereof |
| CN105535439A (en) * | 2016-01-19 | 2016-05-04 | 宁夏金太阳药业有限公司 | Traditional Chinese medicinal composition for treating pharyngitis and preparation method thereof |
| CN108578574A (en) * | 2018-06-08 | 2018-09-28 | 张继梁 | A kind of prescription drug and preparation method thereof for treating pharyngitis |
| CN113750181A (en) * | 2020-06-05 | 2021-12-07 | 西安新润药业有限公司 | Application of traditional Chinese medicine composition in preparation of medicine for treating pharyngitis |
| CN114668811A (en) * | 2022-05-15 | 2022-06-28 | 西安大兴医院 | Chrysanthemum pharyngitis particles for treating chronic pharyngitis and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101422563A (en) * | 2007-10-31 | 2009-05-06 | 北京亚东生物制药有限公司 | Traditional Chinese medicine composition for treating wean sphagitis and preparation method and quality control method thereof |
| CN101985012A (en) * | 2010-11-25 | 2011-03-16 | 中国人民解放军第四军医大学 | Chewable tablet forming process for improving stability and bioavailability of pharyngitis extract |
-
2013
- 2013-02-07 CN CN2013100505868A patent/CN103182023A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101422563A (en) * | 2007-10-31 | 2009-05-06 | 北京亚东生物制药有限公司 | Traditional Chinese medicine composition for treating wean sphagitis and preparation method and quality control method thereof |
| CN101985012A (en) * | 2010-11-25 | 2011-03-16 | 中国人民解放军第四军医大学 | Chewable tablet forming process for improving stability and bioavailability of pharyngitis extract |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103933326A (en) * | 2013-09-22 | 2014-07-23 | 李修奇 | Traditional Chinese medicine formula tea drink for treating chronic pharyngolaryngitis |
| CN104645010A (en) * | 2013-11-22 | 2015-05-27 | 李士干 | Acute and chronic pharyngitis tea and preparation process thereof |
| CN105106646A (en) * | 2015-09-12 | 2015-12-02 | 淄博齐鼎立专利信息咨询有限公司 | Medicinal preparation for treating chronic pharyngitis |
| CN105343503A (en) * | 2015-11-30 | 2016-02-24 | 中国人民解放军第二军医大学 | Medicine composition for treating sphagitis and application thereof |
| CN105343503B (en) * | 2015-11-30 | 2018-10-30 | 中国人民解放军第二军医大学 | A kind of pharmaceutical composition that treating sphagitis and its application |
| CN105535439A (en) * | 2016-01-19 | 2016-05-04 | 宁夏金太阳药业有限公司 | Traditional Chinese medicinal composition for treating pharyngitis and preparation method thereof |
| CN108578574A (en) * | 2018-06-08 | 2018-09-28 | 张继梁 | A kind of prescription drug and preparation method thereof for treating pharyngitis |
| CN113750181A (en) * | 2020-06-05 | 2021-12-07 | 西安新润药业有限公司 | Application of traditional Chinese medicine composition in preparation of medicine for treating pharyngitis |
| CN114668811A (en) * | 2022-05-15 | 2022-06-28 | 西安大兴医院 | Chrysanthemum pharyngitis particles for treating chronic pharyngitis and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103182023A (en) | Medicine for treating chronic pharyngitis and preparation method thereof | |
| CN102198236B (en) | Chinese medicine composition for treating acute sinusitis and preparation method thereof | |
| CN102205026B (en) | Chinese medicinal composition for treating children chronic sinusitis and preparation method thereof | |
| CN102698137B (en) | Composition with blood pressure reducing function and preparation method of same | |
| CN103585433B (en) | Traditional Chinese medicine composition for treating oral ulcer | |
| CN103156984B (en) | Traditional Chinese medicine composition for treating gingivitis and preparation method thereof | |
| CN102836228A (en) | Chinese medicinal composition for treating conjunctivitis and preparation method and application thereof | |
| CN102552769A (en) | Medicine for treating vaginitis and preparation method thereof | |
| CN105213941A (en) | A kind of Chinese medicine composition being used for the treatment of infantile diarrhea and preparation method thereof | |
| CN103182064A (en) | Medicine for treating cough due to wind-cold evil and preparation method thereof | |
| CN103520518B (en) | A kind ofly treat Chinese medicine preparation of chronic non-atrophic gastritis and preparation method thereof | |
| CN104013846A (en) | Traditional Chinese medicine composition for treating dental ulcer and application thereof | |
| CN101129672A (en) | Orally taken traditional Chinese medicine composition for treating bacillary dysentery | |
| CN103182024A (en) | Medicine for treating wind-heat type common cold and preparation method thereof | |
| CN101129923A (en) | Traditional Chinese medicine preparation for treating endometritis | |
| CN103191331A (en) | Traditional Chinese medicine composition for treating bronchial asthma in remission stage | |
| CN102670922B (en) | Traditional Chinese medicine oral fluid with seeds of feather cockscomb for treating diarrhea and preparing method thereof | |
| CN105343346A (en) | Traditional Chinese medicine tablets for treating pruritus vulvae and preparation method thereof | |
| CN105770648A (en) | Oral traditional Chinese medicine preparation for treating cold | |
| CN105169102A (en) | Lung-clearing decoction | |
| CN102247470B (en) | A kind of Chinese medicine composition preventing and treating infant upper respiratory tract infection | |
| CN103182058A (en) | Medicine for treating chronic pelvic inflammatory disease and preparation method thereof | |
| CN109106877B (en) | Traditional Chinese medicine composition for preventing and treating mastitis caused by excessive heat evil of women in lactation period, preparation method and pharmaceutical preparation thereof | |
| CN104689128A (en) | Medicine for treating blood stasis heat type postpartum fever and preparation method thereof | |
| CN105709137A (en) | Traditional Chinese medicine preparation for treating chronic pelvic inflammatory disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130703 |